5.50Open5.50Pre Close0 Volume46 Open Interest77.00Strike Price0.00Turnover0.00%IV-1.63%PremiumNov 1, 2024Expiry Date6.65Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma10.66Leverage Ratio--Theta--Rho--Eff Leverage--Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet